ECX — Epigenomics AG Share Price
Last trade - 00:00- €0.77m
- €10.99m
- €0.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -75.92% | ||
| Return on Equity | -945% | ||
| Operating Margin | -4467.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1.13 | 0.84 | 6.2 | 0.9 | 0.34 | n/a | n/a | -26.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Directors
- Heino.N.F.M Von Prondzynski CSU (71)
- Gregory Hamilton CEO (47)
- Ann Clare Kessler VSU
- Guenther Reiter VSU (63)
- Albert Weber EVF (54)
- Alexander Link SUB
- Helge Lubenow SUB (49)
- Franz Walt SUB (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 29th, 2000
- Public Since
- July 19th, 2004
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Frankfurt Stock Exchange
- Shares in Issue
- 876,949
- Address
- Ziegelhaeuser Landstrasse 3, HEIDELBERG, 69120
- Web
- https://www.epigenomics.com/
- Phone
- +49 62216492487
- Contact
- Frederic Hilke
- Auditors
- Baker Tilly Gmbh & Co. KG
Upcoming Events for ECX
Similar to ECX
4Sc AG
Frankfurt Stock Exchange
bioXXmed AG
Frankfurt Stock Exchange
CureVac NV
Frankfurt Stock Exchange
Diagonal Bio AB
Frankfurt Stock Exchange
Medpace Holdings
Frankfurt Stock Exchange
FAQ
As of Today at 20:29 UTC, shares in Epigenomics AG are trading at €0.88. This share price information is delayed by 15 minutes.
Shares in Epigenomics AG last closed at €0.88 and the price had moved by -43.89% over the past 365 days. In terms of relative price strength the Epigenomics AG share price has underperformed the FTSE Global All Cap Index by -45.3% over the past year.
There is no consensus recommendation for this security.
Find out moreEpigenomics AG does not currently pay a dividend.
Epigenomics AG does not currently pay a dividend.
Epigenomics AG does not currently pay a dividend.
To buy shares in Epigenomics AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.88, shares in Epigenomics AG had a market capitalisation of €0.77m.
Here are the trading details for Epigenomics AG:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: ECX
Based on an overall assessment of its quality, value and momentum Epigenomics AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Epigenomics AG. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +22.32%.
As of the last closing price of €0.88, shares in Epigenomics AG were trading -4.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Epigenomics AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Epigenomics AG's management team is headed by:
- Heino.N.F.M Von Prondzynski - CSU
- Gregory Hamilton - CEO
- Ann Clare Kessler - VSU
- Guenther Reiter - VSU
- Albert Weber - EVF
- Alexander Link - SUB
- Helge Lubenow - SUB
- Franz Walt - SUB